[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account

Clinical Expertise

  • Multiple Myeloma

About

Dr. Landgren is a board-certified hematologist-oncologist whose research focuses on the development of novel treatment strategies and advanced disease monitoring by new minimal residual disease (MRD) assays, as well as biological studies focusing on disease and host biology. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. He has a strong interest in the development of early-treatment clinical trials targeting high-risk smoldering myeloma and is one of the pioneers in the development of MRD testing in myeloma. He develops new strategies (including cell-based, molecular-based, and imaging-based) and implements advanced MRD testing in clinical trials.

Location

University of Miami Sylvester Comprehensive Cancer Center: 1476 NW 12th Ave, Miami, FL 33136, USA

newsletter icon

Get the latest thought leadership on your Multiple Myeloma delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
Pfizer
Genentech
Regeneron
Adaptive

Follow Us

facebook instagram linkedin tiktok youtube